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Drugs that release nitric oxide (NO) usually have limitations due to their harmful effects. Sodium nitro-
prusside (SNP) induces a rapid hypotension that leads to reﬂex tachycardia, which could be an undesir-
able effect in patients with heart disease, a common feature of hypertension. The nitrosyl ruthenium
complex [Ru(terpy)(bdq)NO+]3+ (TERPY) is a NO donor that is less potent than SNP in denuded aortic
rings. This study evaluated the hypotension and vasorelaxation induced by this NO donor in Wistar
(W) and spontaneously hypertensive rats (SHR) and compared to the results obtained with SNP. Differ-
ently from the hypotension induced by SNP, the action of TERPY was slow, long lasting and it did not lead
to reﬂex tachycardia in both groups. The hypotension induced by the NO-donors was more potent in SHR
than in W. TERPY induced relaxation with similar efﬁcacy to SNP, although its potency is lower in both
strains. The relaxation induced by TERPY is similar in W and SHR, but SNP is more potent and efﬁcient
in SHR. The relaxation induced by TERPY is partially dependent on guanylate cyclase in SHR aorta. The
NO released from the NO donors measured with DAF-2 DA by confocal microscopy shows that TERPY
releases similar amounts of NO in W and SHR, while SNP releases more NO in SHR aortic rings.
 2012 Elsevier Inc. Open access under the Elsevier OA license.Introduction
The exogenous administration of nitric oxide (NO) is an attrac-
tive pharmacological alternative in the study and treatment of
hypertension. The chemical versatility of this molecule allows the
synthesis of a wide variety of NO-donors, each one with different
rates of NO release [1–3]. The vasodilatation induced by NO donors
occurs in different ways, depending on the localization where the
NO is released and the mechanism involved in this process [4,5].
The amount of NO released by a donor is a very important factor,
since its cardiovascular actions only occur in very low concentra-
tions, being very toxic in higher concentrations [6,7].
Sodium nitroprusside (SNP) is a classic NO-donor, often used to
verify the relaxation of vascular smooth muscle (VSM) via NO-
cGMP. The molecule of NO is coordinated to an iron metal, forming
an octahedral complex with ﬁve cytotoxic cyanide anions [8–12].
The rapid hypotension evoked by SNP makes it useful in hyperten-
sive emergencies, but the reﬂex tachycardia could be undesirable
for patients with heart disease, a common feature in hypertension.tologia de Araçatuba-UNESP/
io 1193 – CEP: 16015-050 –
.
evier OA license.In this case, NO donors with slower release of NO would minimize
these effects [3,5,13].
Trying to overcome these limitations, newNO-donors have been
developed. Metal complexes of ruthenium have the advantage of
releasing NO in a speciﬁc biological target and the time to reach
maximum relaxation can be modulated according to the structure
and theparticular characteristic of each compound [14]. Thenitrosyl
ruthenium complex [Ru(terpy)(bdq)NO+]3+ (TERPY, Fig. 1) is a NO
donor that is not toxic in the concentrations used to causemaximum
relaxation in isolated aortic rings [15]. In denuded aorta of normo-
tensive or hypertensive rats, TERPY is less potent than SNP and the
vasodilatation induced by both donors is more pronounced in the
aortas of 2K-1C rats [16]. It could be caused by a decrease in the bio-
availability of the NO released by TERPY in 2K-1C rat aorta, com-
pared to the normotensive control [17,18].
In the few studies conducted to evaluate the hypotensive re-
sponse of ruthenium compounds, the blood pressure decrease
was higher in hypertensive (SHR, 2K-1C) in relation to normoten-
sive rats [19,20]. There is no published data regarding the hypoten-
sive effects of TERPY. We hypothesized that in spontaneously
hypertensive rats, the hypotensive and vasorelaxing effects of TER-
PY were altered. Therefore, the aim of the present study was to
evaluate the hypotensive and vasodilatory effects of TERPY in
SHR and to assess the NO released by TERPY in the isolated aorta
of these animals.
Fig. 1. Molecular structure of [Ru(terpy)(bdq)NO+]3+.
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All experiments were approved by the Animal Research Ethics
Committee (CEEA) at the Faculty of Dentistry of Araçatuba, UNESP
(process number 001776-2010).Animals
Spontaneously hypertensive rats (SHR) and normotensive Wis-
tar rats (W) with 120 days were housed under standard laboratory
conditions (12 h light/dark cycle at 21 C with free access to food
and water). The systolic blood pressure (SBP) was evaluated by tail
pletismograph (Narco Biosystems–Houston, Texas, USA). Only SHR
with SBPP 150mmHg were used in this study.Cannulae implantation surgery
Animals anesthetized with Ketamin (45 mg/kg) and Xilasin
(5 mg/kg) had a polyethylene cannula (PE10 connected to PE50)
ﬁlled with heparinized saline implanted into the abdominal aorta,
throughout the femoral artery, for blood pressure recording and
into the femoral vein for administration of the NO-donors. The can-
nulae were exteriorized in the back of the neck and the animals
were kept in standard laboratory conditions for 24 h before the
experiments.Mean arterial pressure measurement
The blood pressure was continuously recorded in conscious rats
using a pressure transducer and an ampliﬁer (ADInstruments) at-
tached to the intra-arterial cannula. The mean arterial pressure
(MAP) in basal conditions and during NO donor administration
was calculated using the software 4 Chart (ADInstruments).Evaluation of the hypotensive effects of the NO-donors
TERPY was dissolved in sodium chloride 0.15 M, protected from
light and stored at 20 C. Before the drug administration, basal
arterial pressure and heart rate were determined by recording
the MAP during 30 min until pressure stabilization. In the same
animal, 5 mg/kg (T5) and 7 mg/kg (T7) of TERPY and 35 lg/kg of
SNP were injected in a random order. These doses were used based
on previous observations from our research group. The DMAP was
calculated using Chart 4 software, based on the difference on the
MAP values at basal condition and until the maximum hypotensive
effect after the drugs administration. The elapsed time from the
initial of the BP decrease up to the ﬁnal hypotensive effect
achieved (T) was also calculated. The heart rate variation (DHR)was calculated through the difference of the basal heart rate values
and the mean of the heart rate after the infusion of the drugs.Vascular reactivity studies
Animals were decapitated and the thoracic aorta was quickly re-
moved, dissected and cut in 4–5 mm rings. The endothelium was
mechanically removed. The aortic rings were placed between two
stainless-steel stirrups and connected to an isometric force trans-
ducer (Letica Scientiﬁc Instruments, Barcelona, Spain) for tension
measurement. They were kept in a chamber containing Krebs solu-
tion with the following composition (mmol/L): NaCl 130.0; KCl 4.7;
KH2PO4 1.2; MgSO4 1.2; NaHCO3 14.9; glucose 5.5 and CaCl2 1.6; pH
7.4 gassed with 95% O2 and 5% CO2 at 37 C. Each ring was stretched
to a 1.5 g resting tension during 60 min for stabilization. During this
period, tissues werewashed every 15 min. The absence of the endo-
thelium was qualitatively assessed by the lack of acetylcholine
(1 lM) induced relaxation in the presence of contractile tone in-
ducedbyphenylephrine (Phe, 0.1 lM).Afterwashing andstabilizing
periods, the ringswere stimulatedwith Phe and cumulative concen-
trations of TERPY (1 nM–100 lM) and SNP (0.1 nM–10 lM) were
added.
The participation of the enzyme soluble guanylate cyclase (sGC)
on TERPY and SNP effects was evaluated by incubation of the aortic
rings with the selective sGC inhibitor 1H-(1,2,4)oxadizolo(4,3-a)-
quinoxalin-1-one (ODQ, 1 lM) for 30 min, before Phe contraction.
Then, cumulative concentration–response curves to TERPY
(1 nM–100 lM) or SNP (0.1 nM–10 lM) were obtained in the pres-
ence of ODQ.Confocal microscopy
Arterial cross-sections of 100 lm thick for each aortic ring were
placed vertically in a glass slide covered with poly-L-lysine. The tis-
sue was loaded with the ﬂuorescent NO dye, diaminoﬂuorescein-2
diacetate (10 lM DAF-2 DA), for 40 min at room temperature in
normal Hanks buffer with the following composition in mM: 1.0
MgCl2, 145.0 NaCl, 5.0 KCl, 0.5 NaH2PO4, 10.0 dextrose and 10.0
HEPES, pH 7.4. After washing, the segment was placed on the con-
focal scanning laser microscope (Leica TCS SP2) and viewed from
the bottom of the chamber through a water-immersion objective
(63). Images of the aortic ring segment were sequentially taken
every 2 s in Hanks buffer (pH 7.4) with 1.6 mM of CaCl2. Nitric
oxide was quantiﬁed by measuring the ﬂuorescence intensity (FI)
by using ﬂuorescent dye DAF-2 DA that intracellularly is converted
to DAF-2T. The cytosolic NO concentration ([NO]c) was assessed by
exciting the DAF-2 DA ﬂuorophore with the 488 nm line of an ar-
gon ion laser and measuring the ﬂuorescence at 515 nm. A time-
course software was used to capture images of the cells at intervals
of 2 s (xyt) in the Live Data Mode acquisition at 512  512 pixel
resolution, at 400 Hz. The protocol was designed to measure
[NO]c in denuded slices of rat aorta. [NO]c was measured in the
slices of aorta before and after addition of the NO donors in the
concentration used to cause maximum relaxation in the vascular
reactivity studies (TERPY – 1 lM, SNP – 10 lM). By applying the
computer software of the LSCM, the intensities of intracellular
maximum or minimum ﬂuorescence were measured. In this way,
the difference in ﬂuorescence intensity (DFI) between the basal
spectrum (F0) and the spectrum recorded after addition of the
NO donor (F) reﬂects the increase in [NO]c, which was calculated
by the formula: DFI = (F  F0). The ﬂuorescence signal used to cal-
culate [NO]c was measured in an area of aortic smooth muscle tis-
sue and averaged. The increase in [NO]c stimulated by each NO-
donor was compared between aortic rings of normotensive and
hypertensive rats.
Fig. 2. Representative recording of the mean arterial pressure (MAP) showing the hypotensive effect of SNP (upper) (in seconds) and TERPY (lower) (in minutes) in SHR. T
indicates the maximum hypotensive effect latency for each NO-donor (Chart 7 – ADInstruments).
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Data are expressed as the mean ± SEM. The in vivo experiments
analyzed the DMAP and the time to reach the maximum effect (T)
and compared between groups. In the vascular reactivity studiesthe maximum effect (Emax) and the potency (pD2) were evaluated.
Emax is deﬁned as the maximal amplitude response reached in the
concentration–effect curves for each relaxant agent. The concentra-
tion of the agent producing the half-maximal relaxation amplitude
(EC50) was determined after logit transformation of the normalized
Fig. 3. (A) Magnitude of the hypotensive effect of intravenous in bolus injections of
SNP (35 lg/kg) and TERPY (5, 7 mg/kg) on the variation of mean arterial pressure
(DMAP) of conscious Wistar (W) and SHR. (B) The maximum effect latency (T) refers
to the elapsed time from the initial of the MAP decrease up to the maximum
hypotensive effect achieved. (C) Heart rate variation (DHR) during the infusion of
the drugs until maximum effect. Data reported as mean ± SEM. ⁄p < 0.05.
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the negative logarithm (pD2) of the mean of individual values for
each tissue. For the confocal studies, the DFI of SNP and TERPY was
evaluated. All the results obtained were compared between normo-
tensive (W) andhypertensive animals (SHR). Statistical analysiswas
performed by Student’s t test using the Graph Pad Prism 5.0 pro-
gram. Differences were considered statistically signiﬁcant when
p < 0.05.Drugs
ACh, Phe, SNP, ODQ and DAF-2DA were obtained from Sigma
Chemical (St Louis, MO, USA). TERPY was synthesized in the labo-
ratory of Dr. Roberto Santana da Silva (Faculty of PharmaceuticalScience of Ribeirão Preto, University of São Paulo, Ribeirão Preto,
São Paulo, Brazil).Results
Hypotensive effects of NO-donors
The basal MAP was increased in SHR (W: 112.7 ± 2.6 mm Hg,
n = 5; SHR: 160.3 ± 3.1 mm Hg, n = 7). SNP and TERPY evoked
hypotensive effects on conscious hypertensive and normotensive
rats. TERPY evoked a slow and long lasting hypotensive effect, in
contrast to the fast and potent effect of SNP (Fig. 2). The effect of
SNP was also higher in SHR (69.3 ± 4.5 mm Hg, n = 7) than in
Wistar (46.7 ± 2.8 mm Hg, n = 5). The magnitude of the hypoten-
sive responses of TERPY was more accentuated in SHR: (T5:
24.5 ± 2.9 mm Hg; T7: 34.8 ± 2.7 mm Hg, n = 7) than in Wistar
rats (T5: 9.7 ± 1.6 mm Hg, n = 5; T7: 17.3 ± 1.3 mm Hg, n = 4)
(Fig. 3A). There were no differences in the time needed to reach
the maximum hypotensive effect of SNP between the groups
(0.5 min in both groups). The time to reach the maximum effect
(T) of TERPY 5 mg/kg was reduced in SHR, however there were
no differences in the T of TERPY 7 mg/kg between the groups (in
min, T5: W: 17.0 ± 2.1; SHR: 11.3 ± 1.5; T7: W: 13.5 ± 1.7; SHR:
9.8 ± 1.5) (Fig. 3B). SNP hypotensive effect was associated with
an increase on heart rate of SHR and Wistar rats (DHR W:
81.8 ± 15.3 bpm, SHR: 96.3 ± 9.1 bpm). However, no alteration of
heart rate was observed during the hypotensive effect of TERPY
(DHR T5: W: 8.9 ± 10.9 bpm, SHR: 6.0 ± 2.8 bpm, T7: W:
16.20 ± 3.88 bpm, SHR: 3.18 ± 6.07 bpm) (Fig. 3C).
Relaxing effect of TERPY in denuded aortic rings
SNP and TERPY evoked vasorelaxation on aortic rings of hyper-
tensive and normotensive rats. TERPY was less potent than SNP in
aortic rings of both groups (Fig. 4A). The Emax induced by SNP is
increased in SHR aortic rings (W: 105.9 ± 3.3%; n = 5; SHR:
118.8 ± 7.3%; n = 5, p <0.05). The potency of SNP was higher in
the aorta of SHR (pD2: 8.74 ± 0.15; n = 5, p <0.05) than in Wistar
(pD2: 7.97 ± 0.07; n = 5). However, the vasodilator effect of TERPY
was not different between Wistar (Emax: 103.5 ± 1.1%, pD2:
6.60 ± 0.08, n = 5) and SHR (Emax: 106.3 ± 4.8%, pD2: 6.25 ± 0.07,
n = 5; Fig. 4B).
Effect of ODQ on the relaxation induced by TERPY in SHR denuded
aortas
In the presence of ODQ (1 lM), the relaxation–response curves
to TERPY were shifted to the right in aortic rings of Wistar (pD2:
4.8 ± 0.08, n = 5; Fig. 5A) and SHR (pD2: 4.9 ± 0.4, n = 5; Fig. 5B).
ODQ reduced the efﬁcacy of TERPY in aortas from Wistar (Emax:
90.2 ± 3.01%, n = 5), but not from SHR (Emax: 97.7 ± 2.7%, n = 5).
ODQ incubation shifted to the right the curves of SNP in Wistar
(pD2: 6.22 ± 0.2, n = 5; Fig. 5C) and SHR (pD2: 7.18 ± 0.13, n = 5;
Fig. 5D). There was no difference in the Emax of SNP in Wistar aor-
tic rings (Emax: 96.57 ± 1.90%, n = 5). In SHR aorta, it reached more
than 100% (Emax: 104.64 ± 7.3%, n = 5) of relaxation, but it was still
not as effective as in the control group (Emax: 142.85 ± 10,7%,
n = 5).
Confocal microscopy
NOmeasurement in the cell milieu was accomplished by confo-
calmicroscopy. The cytosolicNO concentration ([NO]c) in the vascu-
lar smooth muscle of aortic rings was obtained in the absence and
after the addition of SNP (1 lM) or TERPY (10 lM). The DFI after
Fig. 4. The NO donors were cumulatively added in isolated rings previously contracted with phenylephrine (100 nM). (A) Vasodilatation induced by SNP (0.01 nm–1 lM) and
TERPY (1 nm–100 lM) in denuded aortic rings of Wistar (W) and SHR. (B) Comparison of the effect of the drugs between Wistar (W) and SHR denuded aortic rings. The data
are presented as mean ± SEM and presents the percentage of relaxation in relation to the value of the initial contraction. Differences in the pD2 and the Emax were considered
signiﬁcant when p < 0.05.
Fig. 5. The rings were incubated with 1H-(1,2,4)oxadizolo(4,3-a)-quinoxalin-1-one (ODQ) (1 lmol) for 30 min prior to the application of phenylephrine (0.1 lmol). The effect
of (ODQ) on the relaxation induced by the TERPY in denuded rat aortic rings pre-contracted with phenylephrine was studied in Wistar (A) and SHR (B). The effects of ODQ in
the relaxation induced by SNP were also studied in Wistar (C) and SHR (D). Data are means ± SEM of experiments performed on preparations obtained from different animals.
⁄p < 0.05 between pD2 values.
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Fig. 6. Cytosolic concentration of NO in denuded aortic rings of Wistar (W) and SHR. Fluorescence of DAF-2 DA (10 lM) was recorded in slices of aortas before and after the
addition of the NO donors: (A) SNP (1 lM); (B) TERPY (10 lM). The difference in ﬂuorescence intensity (DFI) between the F0 (basal spectrum) and F (spectrum recorded after
addition of the NO-donors) reﬂects the increase in [NO]c, which was calculated by the formula: DFI = (FF0). Fluorescent images of cytosolic concentration of nitric oxide
([NO]c) in a representative slice of rats denuded aorta preloaded with DAF-2 DA. Data are mean ± SEM of experiments performed. Difference between the values of DFI
obtained in aortic rings of SHR and Wistar was considered signiﬁcant when ⁄p < 0.05.
116 F.C. Munhoz et al. / Nitric Oxide 26 (2012) 111–117stimulation with SNP was increased in SHR aorta (18.94 ± 3.19,
n = 4) when compared to Wistar (4.48 ± 1.56, n = 6, Fig. 6A). There
were no differences in DFI of TERPY between Wistar (120.34 ±
9.44, n = 5) and SHR (127.01 ± 21.85, n = 4, Fig. 6B).Discussion
The present data bring the ﬁrst evidence of the hypotensive ef-
fect of TERPY in rats. Opposite to the observed SNP effect, the hypo-
tension induced by this new NO-donor is slow and long lasting and
does not evoke changes in the heart rate (Fig. 2). TERPY is less po-
tent than SNP to induce hypotensive effect. The magnitude of the
hypotensive response to the NO-donors used was more accentu-
ated in SHR than in Wistar rats. There were no signiﬁcant differ-
ences in the duration of the hypotension of the NO-donors in
Wistar or SHR. The only difference found was in the T of TERPY
5 mg/kg, that was slower in SHR (Fig. 3). Few studies evaluated
the hypotensive effect of ruthenium complexes in conscious ani-
mals. de Gaitani et al. [20] have observed that the hypotensive ef-
fect of trans-[RuCl([15]aneN4)NO]2+ (15-ANE) was signiﬁcantly
increased in hypertensive rats (2K-1C) and that was higher in se-
verely hypertensive than in moderately hypertensive 2K-1C rats.
In a study with SHR, de Barros et al. [19] veriﬁed that the hypoten-
sive response of the NO-donor (trans-[Ru(NO)(NH3)4(POEt)3](PF6)3)
was also increased in SHR when compared toWistar rats. However,
in SHR, the hypotensive effect of Ru(NO)(NH3)4(POEt)3(PF6)3 was
higher than the effect of SNP, which differs from the results ob-
tained with TERPY.
In order to understand if the hypotensive effect of TERPY could
be modulated by the vasodilator effect of this drug, the effect of
TERPY was studied in isolated denuded aortic rings. As expected,
TERPY induces relaxation in aortic rings pre-contracted with
phenylephrine in a concentration-dependent manner, but it is less
potent than SNP as demonstrated by previous studies of ourresearch group [17,18]. These results are also in accordance to
Bonaventura et al. [21] and Pereira et al. [22] that have reported
a higher potency of SNP compared to other nitrosyl complexes
(15-ANE and cis-[Ru(bpy)2(py)NO2](PF6) (RuBPY), respectively).
In the present study, the relaxation induced by SNP is more potent
in SHR aorta than in the aorta of normotensive rats, however the
concentration–effect curves of TERPY inWistar and SHR are similar
(Fig. 4). These results differ from results obtained in other hyper-
tensive model. Bonaventura et al. [21] observed that the effect of
the NO-donors SNP and 15-ANE were impaired in 2K-1C rat aorta,
and Rodrigues et al. [17,18] also observed an impaired relaxation
induced by SNP and TERPY in 2K-1C aorta.
To study the mechanism of action of TERPY, we evaluated its
vasorelaxation after incubation with ODQ, a selective sGC inhibitor
[23]. The inhibitory effect of ODQ is due to changes in the oxidation
state of the heme moiety of the enzyme, without adverse effects on
its catalytic activity. Although ODQ has been reported to interfere
with heme-protein-dependent processes [24], it remains the most
selective and potent inhibitor available of sGC. Vascular relaxation
sensitivity to ODQ inhibition is an indicative of a predominant
mechanism of heme site mediated activation of sGC, whereas resis-
tance toward ODQ suggests the possible presence of alternative
mechanisms of vasorelaxation. In the concentration of 1 lM,
ODQ abolished the relaxation induced by TERPY [25] and 15-ANE
[21] in 2K-1C aortas. These results differ from what is observed
in SHR aortas, where the concentration–response curves to TERPY
and SNP, are shifted to the right in the presence of ODQ (1 lM), but
were not abolished (Fig. 5). These results suggest that while the
sGC seems to be the most important pathway involved in relaxa-
tion induced by TERPY in 2K-1C aorta, this NO donor can elicit vas-
cular relaxation in SHR aortas, at least in part, through a pathway
that is independent of the activation of sGC.
To investigate if the amount of NO released by TERPY would ac-
count for the similar results of vascular reactivity between Wistar
and SHR, the NO concentration in the vascular smooth muscle of
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determined by using the NO sensitive dye, DAF-2 DA (Fig. 6). It was
observed that the NO concentration is enhanced after the NO do-
nors addition. Considering that NO was measured in denuded aor-
tic rings, the enhanced ﬂuorescence from the bound DAF can be
attributed to NO release, as demonstrated by previous observa-
tions [17,18,22]. Through this technique, it was possible to verify
that when SNP was added, the amount of NO sensitive dye was sig-
niﬁcantly increased in SHR aortic rings, which did not occur when
the NO was released from TERPY. SNP is thought to exert its vaso-
dilator action, at least in part, by NO release inside the vascular
smooth muscle cell. Thus, a greater amount of NO released by
SNP in SHR aortic rings could be associated to the higher potency
of this NO-donor in the aortic relaxation of SHR. So, our results sug-
gest that NO concentration released by each NO-donor could be di-
rectly related to the vasodilator response of SHR aorta.
The cellular alterations that lead to the differences observed in
2K-1C aorta may not be the same observed in the aorta of SHR.
These differences could be related the way that the different NO-
donors are reduced, before NO release [1,4] and/or to the mecha-
nism of the relaxing response of the vascular smooth muscle, as
activation of potassium channels and cGMP accumulation
[18,21]. These possible differences are currently being explored
in our laboratory.
The present results still cannot point the reason for the differ-
ences observed in the hypotensive effect of the drugs, but these
data brings more evidence that drugs that slowly release NO could
be used as a target in the comprehension of the mechanisms in-
volved in NO-induced hypotension in SHR, as well as the mecha-
nism of NO release and smooth muscle relaxation evoked by NO-
donors, as pharmacological tools in the study of the vasodilatory
and hypotensive processes. Besides, NO-donors that do not induce
reﬂex tachycardia could be attractive when alterations in the heart
rhythm are undesirable.Acknowledgments
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